Age- and weight-adjusted warfarin initiation nomogram for ischaemic stroke patients

European Journal of Neurology

Volumn 19, Issue 12, 2012, Pages 1547-1553

  Yoo, S H ^a   Kwon, S U ^a   Jo, M W ^a   Kang, D W ^a   Kim, J S ^a  

^a University of Ulsan College of Medicine   (South Korea)

Author keywords

Ischaemic stroke; Warfarin initiation nomogram

Indexed keywords

HEPARIN; NADROPARIN; WARFARIN;

ADULT; AGE; AGED; ANTICOAGULATION; ARTICLE; BODY WEIGHT; BRAIN ISCHEMIA; CONTROLLED STUDY; DISEASE COURSE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; FEMALE; HOSPITALIZATION; HUMAN; INTERNATIONAL NORMALIZED RATIO; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; NOMOGRAM; OUTCOME ASSESSMENT; PHYSICIAN ATTITUDE; PRACTICE GUIDELINE; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; TREATMENT DURATION;

AGE FACTORS; AGED; ANTICOAGULANTS; BODY WEIGHT; FEMALE; HUMANS; INTERNATIONAL NORMALIZED RATIO; MALE; MIDDLE AGED; NOMOGRAMS; RISK FACTORS; STROKE; WARFARIN;

EID: 84869491591     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/j.1468-1331.2012.03772.x     Document Type: Article

References (20)

1. Furie KL, Kasner SE, Adams RJ, et al. Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2011; 42: 227-276.
2. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139-1151.
3. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365: 883-891.
4. Gulseth MP, Wittkowsky AK, Fanikos J, Spinler SA, Dager WE, Nutescu EA. Dabigatran etexilate in clinical practice: confronting challenges to improve safety and effectiveness. Pharmacotherapy 2011; 31: 1232-1249.
5. Kovacs MJ, Rodger M, Anderson DR, et al. Comparison of 10-mg and 5-mg warfarin initiation nomograms together with low-molecular-weight heparin for outpatient treatment of acute venous thromboembolism. A randomized, double-blind, controlled trial. Ann Intern Med 2003; 138: 714-719.
6. Wells PS, Le Gal G, Tierney S, Carrier M. Practical application of the 10-mg warfarin initiation nomogram. Blood Coagul Fibrinolysis 2009; 20: 403-408.
7. Crowther MA, Ginsberg JB, Kearon C, et al. A randomized trial comparing 5-mg and 10-mg warfarin loading doses. Arch Intern Med 1999; 159: 46-48.
8. Yoo SH, Nah HW, Jo MW, et al. Age and body weight adjusted warfarin initiation program for ischaemic stroke patients. Eur J Neurol 2009; 16: 1100-1105.
9. Chimowitz MI, Lynn MJ, Howlett-Smith H, et al. Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis. N Engl J Med 2005; 352: 1305-1316.
10. Qureshi AI, Feldmann E, Gomez CR, et al. Intracranial atherosclerotic disease: an update. Ann Neurol 2009; 66: 730-738.
11. Adams HP Jr, Bendixen BH, Kappelle LJ, et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke 1993; 24: 35-41.
12. Salem DN, Stein PD, Al-Ahmad A, et al. Antithrombotic therapy in valvular heart disease - native and prosthetic: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126: 457S-482S.
13. Hirsh J, Fuster V, Ansell J, Halperin JL. American Heart Association/American College of Cardiology Foundation guide to warfarin therapy. Circulation 2003; 107: 1692-1711.
14. Zhu Y, Shennan M, Reynolds KK, et al. Estimation of warfarin maintenance dose based on VKORC1 (-1639 G>A) and CYP2C9 genotypes. Clin Chem 2007; 53: 1199-1205.
15. Kovacs MJ, Cruickshank M, Wells PS, et al. Randomized assessment of a warfarin nomogram for initial oral anticoagulation after venous thromboembolic disease. Haemostasis 1998; 28: 62-69.
16. Rieder MJ, Reiner AP, Gage BF, et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med 2005; 352: 2285-2293.
17. Klein TE, Altman RB, Eriksson N, et al. Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med 2009; 360: 753-764.
18. Eckman MH, Greenberg SM, Rosand J. Should we test for CYP2C9 before initiating anticoagulant therapy in patients with atrial fibrillation? J Gen Intern Med 2009; 24: 543-549.
19. Kangelaris KN, Bent S, Nussbaum RL, Garcia DA, Tice JA. Genetic testing before anticoagulation? A systematic review of pharmacogenetic dosing of warfarin. J Gen Intern Med 2009; 24: 656-664.
20. Herman D, Locatelli I, Grabnar I, et al. Influence of CYP2C9 polymorphisms, demographic factors and concomitant drug therapy on warfarin metabolism and maintenance dose. Pharmacogenomics J 2005; 5: 193-202.